The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. After-hours trades for Plus Therapeutics Inc. (PSTV) shows that investor sentiment remained broken, with the stock’s consolidated last price falling by -$0.008, or -1.65%, to $0.478. Volume reached 30,649 shares, with price reaching a high of $0.4999 and a low of $0.456. The stock was recently discussed on Yahoo Finance as it revealed that Plus Therapeutics Executes $17.6 Million Award Contract with Cancer Prevention & Research Institute of Texas.
The company is listed on the NASDAQ and operates within the Biotechnology industry segment. At the end of the last regular session, the stock closed at $0.49 and fluctuated between $0.5248 as its day high and $0.4600 as its day low. The current market capitalization of Plus Therapeutics Inc. is $16.25M. A total of 3.0 million shares were traded on the day, compared to an average of 4.07M shares.
Furthermore, investors take into consideration insider trades when predicting a stock’s future trajectory. During the recent three months, PSTV has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 9 BUYs and 0 SELLs from insiders. Insiders purchased 72,500 shares during that period but sold 0.
In the most recent transaction, HEDRICK MARC H bought 5,000 shares of PSTV for 0.65 per share on Jun 15. After the transaction, the Chief Executive Officer now owns 33,580 company shares. In a previous transaction on Jun 02, Clowes Howard bought 15,000 shares at 0.57 per share. PSTV shares that Director owns now total 18,000.
Among the insiders who bought shares, Petersen Greg acquired of 30,000 shares on May 17 at a per-share price of $0.55. This resulted in the Director holding 62,500 shares of PSTV after the transaction. In another insider transaction, HEDRICK MARC H bought 2,500 shares at $0.68 per share on Apr 26. Company shares held by the Chief Executive Officer now total 28,580.
It has been observed that price targets are rarely accurate, but they can exert some influence from time to time, and are often accepted as valuable in the market. According to analysts who have offered 12-month price targets for PSTV in the last 3 months, the mean price target is $3.50 with high estimates of $5.00 and low estimates of $2.00. In terms of 52-week highs and lows, PSTV has a high of $2.16 and a low of $0.39.
As of this writing, PSTV has an earnings estimate of $-0.21 per share for the current quarter. EPS was calculated based on a consensus of 1 estimates, with a high estimate of $-0.21 per share and a lower estimate of $-0.21. The company reported an EPS of $-0.24 in the last quarter, which was -33.33% lower than expectations of $-0.18.
Balance Sheet Annually/Quarterly
An equity investor’s investment can be viewed on a balance sheet by looking at what assets and liabilities the company has. Investors can determine the company’s prospects by calculating its financial ratios based on this information.
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. Currently, 3 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for PSTV is Buy with a score of 5.00. A total of 3 analysts rated the stock as Buy while 0 rated it as Overweight while 0 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.